Shattuck Labs, Inc. Other Income and Expense
Shattuck Labs, Inc. (STTK) reported Other Income and Expense of $1.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-11
- Shattuck Labs, Inc. nonoperating income (expense) for the quarter ending 2026-06-30 was $1.00M, a 74.74% increase year-over-year.
- Shattuck Labs, Inc. nonoperating income (expense) for the quarter ending 2026-03-31 was $778.00K, a 13.25% increase year-over-year.
- Shattuck Labs, Inc. nonoperating income (expense) for the quarter ending 2025-06-30 was $574.00K.
- Shattuck Labs, Inc. nonoperating income (expense) for the quarter ending 2025-03-31 was $687.00K.
- Shattuck Labs, Inc. nonoperating income (expense) for fiscal 2025 was $2.70M, a 47.66% decline from fiscal 2024.
- Shattuck Labs, Inc. nonoperating income (expense) for fiscal 2024 was $5.16M, a 10.69% increase from fiscal 2023.
- Shattuck Labs, Inc. nonoperating income (expense) for fiscal 2023 was $4.66M, a 236.63% increase from fiscal 2022.
- Shattuck Labs, Inc. nonoperating income (expense) for fiscal 2022 was $1.38M, a 369.15% increase from fiscal 2021.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-08-11 | $1.78M 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $778.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $2.70M 10-K · filed 2026-03-05 | |||
| 2025-06-30 | $574.00K 10-Q · filed 2026-08-11 | $1.26M 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | $687.00K 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $5.16M 10-K · filed 2026-03-05 | |||
| 2023-12-31 | $4.66M 10-K · filed 2025-03-27 | |||
| 2022-12-31 | $1.38M 10-K · filed 2024-02-29 | |||
| 2021-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$1.23M derived: sum of 2 quarters · filed 2023-02-23 | -$315.00K derived: sum of 3 quarters · filed 2023-02-23 | $295.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $170.00K 10-Q · filed 2021-11-09 | $1.08M derived: sum of 2 quarters · filed 2021-11-09 | $1.69M 10-Q · filed 2021-11-09 | $1.69M derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-06-30 | $914.00K 10-Q · filed 2021-08-12 | $1.52M 10-Q · filed 2021-08-12 | $1.52M derived: sum of 3 quarters · filed 2022-03-15 | $1.53M derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-03-31 | $610.00K 10-Q · filed 2021-05-10 | $609.00K derived: sum of 2 quarters · filed 2022-03-15 | $619.00K derived: sum of 3 quarters · filed 2022-03-15 | $731.00K derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $9.00K derived: sum of 2 quarters · filed 2022-03-15 | $121.00K derived: sum of 3 quarters · filed 2022-03-15 | $328.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | $10.00K 10-Q · filed 2021-11-09 | $122.00K derived: sum of 2 quarters · filed 2021-11-09 | $329.00K 10-Q · filed 2021-11-09 | $584.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $112.00K 10-Q · filed 2021-08-12 | $319.00K 10-Q · filed 2021-08-12 | $574.00K derived: sum of 3 quarters · filed 2021-08-12 | $822.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $207.00K 10-Q · filed 2021-05-10 | $462.00K derived: sum of 2 quarters · filed 2021-05-10 | $710.00K derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | $255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $503.00K derived: sum of 2 quarters · filed 2021-03-16 | $1.08M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $248.00K 10-Q · filed 2020-11-13 | $830.00K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |